CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: June 1, 2011
Result type: Reports
Project Number: SR0234-000
Product Line: Reimbursement Review

Generic Name: Ticagrelor

Brand Name: Brilinta

Manufacturer: AstraZeneca Canada Inc

Therapeutic Area: Acute coronary syndromes

Indications: Thrombotic events in Acute Coronary Syndromes, Prevention

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 16, 2011

Recommendation Type: Do not list